Patch Forward Prize

The Biomedical Advanced Research and Development Authority (BARDA) concluded the Patch Forward Prize in 2025 to refocus innovation investments in alignment with HHS priorities.

We thank all participating experts and participants for their contributions and encourage innovators to explore the Single Shield Prize, where the agency continues to invest in solutions that protect and strengthen public health.

Meet the Concept Stage winning teams

LTS Lohmann, partnered with BioNet

A next-generation microneedle patch-based mRNA vaccine targeting seasonal influenza viruses, with the flexibility to pivot to pandemic influenza strains.

Micron Biomedical, partnered with Zipcode Bio

Co-developing mRNA-based, broadly protecting influenza vaccines based on dissolvable microarrays and delivered without an injection.

PopVax, partnered with LTS Lohmann

A seasonal influenza vaccine built on a novel mRNA-encoded immunogen display architecture delivered via a dissolvable microarray patch.

Vaxxas, partnered with University of Queensland/BASE

A high-density microarray patch-based mRNA vaccine for COVID-19 designed for enhanced immunity.